Repligen Corp. has announced results of a Phase 2b clinical trial of RG2417, an oral formulation of uridine, in patients with bipolar depression.
The study did not demonstrate a statistically significant improvement in the symptoms of depression in all patients receiving RG2417 when compared to placebo over the eight-week treatment period. However, preliminary analysis indicates that the subset of patients (n=50) enrolled through academic medical centers showed a clinically meaningful improvement on the Montgomery-Asberg Depression Rating Scale (MADRS) score from weeks 2 through 8 when compared to placebo.
No difference was observed between RG2417 and placebo for patients (n=125) enrolled at the commercial clinical trial sites. A similar pattern of response was observed with several of the secondary endpoints. It was well tolerated and there were no serious adverse events related to drug treatment.
"While we are disappointed with the top-line results of the study, we plan to conduct further evaluation of the data including the observation of differences between the patients treated in academic and commercial sites to determine if there is a path forward with RG2417," said Walter C. Herlihy, Repligen's president and CEO. This was a double-blind, placebo-controlled trial in which 175 patients were enrolled at 12 academic and 17 commercial study sites, and randomized on a 1:1 basis to receive either RG2417 or a placebo twice a day for eight weeks. Patients in the RG2417 and placebo groups were clinically and statistically well matched in their symptoms at baseline.
Evaluations for symptoms of depression were conducted at baseline and then weekly using the MADRS, a standardized, rater-administered scale, which has been used for numerous drug trials in bipolar disorder. In addition, patients conducted a weekly self-assessment of their symptoms, referred to as a patient-based MADRS. Additional secondary objectives included the Clinical Global Impression scale, subset analysis of patients based on prior episodes of depression, responder rates and remission rates.
- Scientists identify susceptibility factor for bipolar disorder
- Fluctuating hormones linked to more severe bipolar symptoms
- Abilify approved as adjunct to lithium or valproate for Bipolar I Disorder maintenance treatment
- University study to evaluate bipolar disorder meds
- Rep. Kennedy endorses stigma-reducing initiative Brilliance in Bipolar
- National Council webcast dispels schizophrenia, bipolar myths
- NIH expands pharmacogenomics research to include bipolar disorder
- Survey reveals hidden bipolarity in many depressed respondents